Internet of Events
Leaderboard
Traders
Markets
Hot Bets
Surveillance
Pricing
Log in
Get Access
Accrue
/
Home
/
Manifold Markets
/
Will Nuvalent (NUVL) stock gain more than 7% on Nov 17 upon topline data release for ALKOVE-1 Trial of Neladalkib?
Manifold
Resolved: YES
BINARY · cpmm-1
Will Nuvalent (NUVL) stock gain more than 7% on Nov 17 upon topline data release for ALKOVE-1 Trial of Neladalkib?
Yes
99%
Yes Pool
$10
No Pool
$995
Resolution
YES